At Moffitt, we offer a large range of treatment options for patients with lymphoma or myeloma. Our team integrates the latest imaging modalities to assess the response to therapy and design appropriate radiation fields. Although external beam with 3D CRT, IMRT and IGRT is the main treatment modality, we also offer internal radiation with radiopharmaceuticals (Bexxar, Zevalin, and radiolabeled monoclonal antibodies). We have extensive experience treating patients with these disease types; our team leader, Dr. Michael Tomblyn, is an international expert in radiopharmaceuticals and is building a center of excellence at Moffitt.
Michael Tomblyn, M.D., M.S.